{"id":151472,"date":"2025-11-25T04:58:20","date_gmt":"2025-11-25T04:58:20","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/151472\/"},"modified":"2025-11-25T04:58:20","modified_gmt":"2025-11-25T04:58:20","slug":"were-reading-about-novo-alzheimers-trials-bayer-stroke-results","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/151472\/","title":{"rendered":"We\u2019re reading about Novo Alzheimer\u2019s trials, Bayer stroke results"},"content":{"rendered":"<p>Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have always detested that dry, tasteless bird. (It\u2019s sides and brisket for me, followed by pecan pie.) So in their interest, I leave you with this story, from 2018, about <a href=\"https:\/\/www.theatlantic.com\/ideas\/archive\/2018\/11\/yellville-turkey-trot\/576184\/\" target=\"_blank\" rel=\"noopener nofollow\">the Ozark turkeys that fell from the sky.<\/a> A trajectory not unlike Novo Nordisk\u2019s stock, after today\u2019s news. \u2026<\/p>\n<p>Novo Nordisk\u2019s weight loss drug semaglutide failed to slow the progression of Alzheimer\u2019s disease in two large trials, STAT <a href=\"https:\/\/www.statnews.com\/2025\/11\/24\/novo-nordisk-semaglutide-wegovy-ozempic-alzheimers-trial-failure\/\" rel=\"nofollow noopener\" target=\"_blank\">reports<\/a>. The results will, for now, quiet excitement around a darkhorse theory for treating Alzheimer\u2019s that had percolated over the last few years, based on retrospective studies that suggested patients taking the drug had lower risk of dementia, possibly because it dampened inflammation. Executives at Novo, which is down 10% today, had long warned the studies were risky.<\/p>\n<p>Bayer said its experimental drug asundexian slashed the risk of recurrent stroke in a Phase 3 study, Endpoints News <a href=\"https:\/\/endpoints.news\/bayers-stock-rallies-as-next-gen-blood-thinner-beats-the-odds-with-phase-3-win\/\" target=\"_blank\" rel=\"noopener nofollow\">relays<\/a>. Asundexian is a factor XIa inhibitor, a class of drugs that has had mixed results in clinical trials so far. Bristol Myers Squibb and Johnson &amp; Johnson recently cut their own Phase 3 trial of a XIa inhibitor in a different indication, saying it was unlikely to succeed. A Phase 3 for stroke recurrence for that drug is still underway. Bayer has yet to release detailed data.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2025\/09\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Good morning, Jason Mast here filling in for Ed. Happy turkey week to all. I, for one, have&hellip;\n","protected":false},"author":2,"featured_media":132185,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[163,521,85,46,82578,15830],"class_list":{"0":"post-151472","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-health","9":"tag-healthcare","10":"tag-il","11":"tag-israel","12":"tag-pharmalittle","13":"tag-stat"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/151472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=151472"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/151472\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/132185"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=151472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=151472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=151472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}